BioCentury | Jun 20, 2019
Distillery Techniques

TMEM16A as a marker for survival in pancreatic cancer

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling A study from Lily Yeh Jan and Yuh Nung Jan at UCSF suggests that tumor levels of TMEM16A could help predict survival in pancreatic cancer patients, and...
BioCentury | May 17, 2019
Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
BioCentury | Aug 1, 2018
Distillery Therapeutics

Neurology

INDICATION: Epilepsy Cell culture and rat studies suggest gene therapy delivering an engineered mutant chloride channel could help treat focal epilepsy. The mutant is a Caenorhabditis elegans glutamate-gated chloride channel engineered for increased sensitivity to...
BioCentury | Jul 26, 2018
Translation in Brief

Closing the loop

A University College London team has developed a chemogenetically activated gene therapy for refractory focal epilepsy that inhibits seizure-generating neurons in response to increased extracellular glutamate levels, a hallmark of seizures. The approach could provide...
BioCentury | Apr 13, 2018
Financial News

Enterprise raises £29M series B

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and...
BioCentury | Apr 12, 2018
Financial News

Versant, Novartis Venture lead £29M round for Enterprise

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and existing investors Epidarex...
BioCentury | Apr 12, 2018
Finance

Enterprise engages

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round. Versant Ventures and Novartis Venture...
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
BioCentury | Jan 3, 2018
Product R&D

Expanding small molecule horizons

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco...
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
Items per page:
1 - 10 of 224